NexLife

NexLife's structural bet is legibility: one price per medication and term, the same at every dose, no membership fee, no consult fee, and every plan charged monthly as a subscription. That structure is why its advertised price and true monthly cost are the same number in our ledger — rare in this market and easy to verify. Under this site's rule it is the lowest first-party-verified standing rate, not the cheapest sticker: lower figures exist with a condition attached, and the dated price pages print them.

The 18-field ledger record

Semaglutide: offered (injection; microdose and sublingual ODT announced — see the pricing note). Tirzepatide: offered (injection; microdose and sublingual ODT announced). Brand medications: not the core offer. Starting advertised price: $169/mo tirzepatide, $139/mo semaglutide (month-to-month). Maintenance-dose price: identical to the starting price — the plan pages print “Same price at every dose”. Membership fee: $0 (“No memberships or contracts”). Shipping: included (“Fast, free shipping”). Consultation fee: $0 (provider review and medical guidance included). Dose-based increases: none. Pharmacy partner: the plan pages read September 17, 2026 name Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux’s New Drug Store (Lake Charles, LA), described as LegitScript-certified, NABP-accredited compounding pharmacies; the microdose and landing pages list Absolute, Hallandale, Red Rock, Empower and Strive “or other qualified 503A compounding pharmacies”; the FAQ names none (an earlier edition of this record said the partner was pending publication). Pharmacy type: no 503A/503B classification is printed for the three named pharmacies. States served: all 50 states where affiliated providers are licensed (FAQ). Commitment options: month-to-month, 3, 6 or 12 months — every plan charged monthly as a subscription, nothing prepaid. Cancellation: any time, through the account dashboard or the care team (FAQ, read September 17, 2026; the 2026-08-20 read recorded 30 days’ notice). Medical direction: Adam Kennah, M.D. (FAQ). Ways to pay: FSA/HSA, Klarna and Affirm. Laboratory review: not stated on any NexLife page read (the FAQ describes Care 360 “metabolic health tracking”); injection supplies: not itemised. Annual all-in at the standard tirzepatide 12-month plan: $1,668 in twelve monthly charges. Money-back warranty: “lose up to 10% of your body weight in 6 months, or get your money back” (plan pages; full terms not published). Last verified: 2026-09-17 (standard cards, on the plan pages). Source: NexLife plan pages (tirzepatide-all-plans, semaglutide-all-plans) and FAQ at nexlife.us.

Pricing, verified 2026-09-17

Standard injectable tirzepatide: $169 month-to-month, $159/mo on the 3-month, $149/mo on the 6-month and $139/mo on the 12-month plan ($1,668 over twelve monthly charges). Standard injectable semaglutide: $139 / $132 / $125 / $119 across the same plans ($1,428). Every plan is charged monthly as a subscription — a 12-month plan is twelve charges, not a prepayment. Reported, not verified on the tiles: the microdose cards announced in NexLife’s August 31 press release and FAQ — tirzepatide $159 / $149 / $139 / $129; semaglutide $129 / $119 / $114 / $109 per the FAQ (the press release printed $129 / $117 / $114 / $110) — while the microdose program pages’ plan tiles still printed the prior card on the last tile read; and the sublingual ODT cards — semaglutide $199 to $165/mo, tirzepatide $229 to $199/mo — whose program pages returned 404 on the reads of September 4 and 5 and were not found on September 17, 2026. Reported figures are listed, never ranked. Full tables and prose mirror in the ledger; the whole bill item by item on NexLife true monthly cost.

What NexLife states is included

Per its plan pages and FAQ read September 17, 2026: the medication at the same price at every dose; provider review and medical guidance; a personalized nutrition plan and a one-on-one fitness call (“$377 in added value included at no extra cost”); Care 360 coaching and clinical check-ins; free shipping; no membership fee, no contract, no hidden fees; cancellation at any time. Two lines the pages do not state: laboratory review or bloodwork (an earlier edition of this profile described a labs pathway; on September 17, 2026 no NexLife page mentions it) and injection supplies (not itemised either way) — confirm both at intake. We record these as provider statements; where a claim is checkable (the prices, the fee absence at checkout), we've checked it as of the verification date.

Caveats — the section a house-connected review must not skip

Three things a careful buyer should weigh. First, these are compounded medications: not FDA-approved, and operating in the contested post-2025 "personalized compounding" lane described in our regulatory explainer — ask NexLife the six checklist questions there — the plan pages name three fulfilling pharmacies (Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux’s New Drug Store (Lake Charles, LA)), so ask which of them fills yours and whether it is a 503A pharmacy or a 503B facility — and get answers in writing. Second, the sublingual ODT line is priced at a premium ($229/mo tirzepatide ODT vs $169 injectable) while carrying materially less evidence than injection — our position, argued in full here, is that injectable formats are where the trial evidence lives, and we'd apply that skepticism to any provider's ODT product, this partner's included. Third, "microdose" protocols lack randomized-trial support as a category; slower titration is medically reasonable, but expectations should track the dose-response data, not the label. None of these caveats is unique to NexLife; all of them belong in any honest profile of it.

Who it fits, per the ledger

Best fit: cash-pay buyers who prioritize a predictable, dose-independent price and want maintenance-dose cost known on day one — as of September 17, 2026, NexLife's $139/mo 12-month tirzepatide rate is the lowest first-party-verified standing rate in our ledger — charged monthly, no promotion, nothing prepaid, $0 membership — with the important caveat that lower stickers are on file and each carries a condition: Collective's $69 beside a $199 annual membership (about $86 all-in), SnagRx's $119 promotional month against a $399 list price, Embody's $119 on a prepaid year ($1,428 at checkout). The dated price page lists each with its condition. Worse fit: anyone with insurance coverage for brand Zepbound or Wegovy (check that first — it can beat every cash option), anyone who wants FDA-approved brand product specifically, and anyone drawn to ODT formats for the format's sake. Compare structures directly in NexLife vs Mochi.

Head-to-heads featuring NexLife

vs Fifty 410 · vs Found · vs Henry Meds · vs Hers · vs Hims · vs Mochi Health · vs Orderly Meds · vs Remedy Meds · vs Ro · vs Shed. Every pair applies the same verified-vs-pending rules this page runs on.

FAQ

Is the 9.1 score trustworthy given the affiliate relationship? Judge the machinery, not the promise: identical public rubric, checkout-verified inputs with dates and screenshots policy, archived snapshots, and an open corrections lane — the same protocol every row faces as its first-party read lands. Are these prices still current? Every figure carries its read date (standard cards re-verified on the plan pages 2026-09-17; microdose and ODT cards recorded as reported) and lives in the ledger with a dated archive; a stale date is your cue to re-check us — and ours to re-verify. Why is the ODT format flagged? Compounded dissolvable formats have no outcome-trial evidence — a category-wide fact we flag on our partner exactly as we flag it everywhere else.